Pyrrolidylidene, piperidylidene and hexahydroazepinylidene ureas as CNS depressants
AssigneeMcNeil Laboratories, Incorporated
InventorsChris Royce Rasmussen, Joseph Francis Gardocki, James Nelson Plampin
Life of this patent
Estimating the term…
Abstract
Compounds of the class of 1-aryl-3-pyrrolidylidene ureas, 1-aryl-3-piperidylidene ureas and 1-aryl-3-hexahydroazepinylidene ureas, useful as central nervous system (CNS) depressants.
Claims8
A process of alleviating muscular pain which comprises systemically administering to a subject with such pain a pharmaceutical composition in dosage unit form comprising per dosage unit from about 50 to about 400 mg of a member selected from the group consisting of a compound of the formula:
- ##STR14## wherein n is the integer 1, 2 or 3, R is a member selected from the group consisting of hydrogen and loweralkyl, R.sub.1 is a member selected from the group consisting of loweralkyl and benzyl, R.sub.2 is a member selected from the group consisting of hydrogen and loweralkyl, and Ar is a member selected from the group consisting of di-halophenyl, di-loweralkylphenyl, di-loweralkoxyphenyl, di-trifluoromethylphenyl, loweralkyl-halophenyl, loweralkoxy-halophenyl, benzyloxy-halophenyl, trifluoromethylhalophenyl and nitro-halophenyl, provided that when said n is 2 or 3, then said R is hydrogen and said R.sub.1 is loweralkyl, and the therapeutically active acid addition salts thereof in admixture with a pharmaceutical carrier.
A process of alleviating muscular pain which comprises systemically administering to a subject with such pain a pharmaceutical composition in dosage unit form comprising per dosage unit from about 50 to about 400 mg of a member selected from the group consisting of a compound of the formula:
- ##STR15## wherein Ar.sup.2 is a member selected from the group consisting of di-halophenyl, di-loweralkylphenyl and loweralkyl-halophenyl, and the therapeutically active acid addition salts thereof in admixture with a pharmaceutical carrier.
A process of alleviating muscular pain which comprises systemically administering to a subject with such pain a pharmaceutical composition in dosage unit form comprising per dosage unit from about 50 to about 400 mg of a member selected from the group consisting of 1-(2,6-dimethylphenyl)-3-(1-methyl-2-pyrrolidylidene)urea and the therapeutically active acid addition salts thereof in admixture with a pharmaceutical carrier.
A process of alleviating muscular pain which comprises systemically administering to a subject with such pain a pharmaceutical composition in dosage unit form comprising per dosage unit from about 50 to about 400 mg of a member selected from the group consisting of 1-(2,6-dichlorophenyl)-3-(1-methyl-2-pyrrolidylidene)urea and the therapeutically active acid addition salts thereof in admixture with a pharmaceutical carrier.
A process of alleviating muscular pain which comprises systemically administering to a subject with such pain a pharmaceutical composition in dosage unit form comprising per dosage unit from about 50 to about 400 mg of a member selected from the group consisting of 1-(2-chloro-6-methylphenyl)-3-(1-methyl-2-pyrrolidylidene)urea and the therapeutically active acid addition salts thereof in admixture with a pharmaceutical carrier.
A pharmaceutical composition for relaxing skeletal muscle in dosage unit form comprising per dosage unit from about 50 to about 400 mg of a member selected from the group consisting of 1-(2,6-dimethylphenyl)-3-(1-methyl-2-pyrrolidylidene)urea and the therapeutically active acid addition salts thereof as an active ingredient in admixture with a pharmaceutical carrier.
Dependencies are inferred from the claim text.